Montelukast Combix

Montelukast, the active ingredient in Montelukast Combix, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is indicated for the management of asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in children and adults.

GNH USA supplies Montelukast Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. Montelukast Combix is manufactured under EU GMP guidelines and exported to multiple regions.

Montelukast acts on the leukotriene pathway to control inflammatory airway diseases.

Asthma: reduces frequency of exacerbations and improves lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness

Serious or Rare Side Effects: - Allergic reactions (rash, angioedema) - Neuropsychiatric events (mood changes, suicidal thoughts) - Hepatic enzyme elevation - Stevens‑Johnson syndrome - Anaphylaxis

When prescribing Montelukast, clinicians should consider several safety and handling measures.

Assess asthma control before initiating: ensure baseline disease status is stable. Monitor for neuropsychiatric symptoms: watch for mood changes or depression. Use with caution in hepatic impairment: dose adjustment may be required. Not for acute asthma attacks: it does not replace rescue bronchodilators. Avoid in patients with known hypersensitivity: discontinue if allergic reaction occurs. Store at room temperature: keep in original pack, protect from moisture.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy. - Phenobarbital may increase clearance and lower plasma levels. - Ketoconazole (CYP3A4 inhibitor) may increase exposure.

Moderate Interactions (Monitor Closely): - Concurrent leukotriene modifiers (zafirlukast) may increase risk of side effects. - Warfarin: monitor INR as montelukast may affect plasma protein binding. - Beta‑agonists: observe for additive bronchodilation effects.